Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Nektar Therapeutics clinical trials
The registry lists 39 studies whose lead sponsor is Nektar Therapeutics. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 21, 2026.
Keep track of what changes. Save the Nektar Therapeutics studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Nektar Therapeutics.
- Nektar Therapeutics39 studiesSame company
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 39 of 39.
- A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisRecruitingNCT07690371Phase 3
- A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisRecruitingNCT07711418Phase 3
- NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaTerminatedNCT05664217Phase 2/3
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)CompletedNCT06340360Phase 2
- A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisActive, not recruitingNCT06136741Phase 2
- Study of NKTR 255 in Combination With Cetuximab in Solid TumorsCompletedNCT04616196Phase 1/2
- A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)CompletedNCT04433585Phase 2
- A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19CompletedNCT04646044Phase 1
- A Study of LY3471851 in Participants With PsoriasisCompletedNCT04119557Phase 1
- A Study of LY3471851 in Participants With EczemaCompletedNCT04081350Phase 1
- A Phase I Study of LY3471851 in Healthy ParticipantsCompletedNCT05565729Phase 1
- A Study of LY3471851 in Healthy ParticipantsCompletedNCT04133116Phase 1
- A Study of NKTR-358 (LY3471851) in Healthy ParticipantsCompletedNCT04380324Phase 1
- A Single-Dose Study of LY3471851 in Healthy ParticipantsCompletedNCT04998487Phase 1
- A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)CompletedNCT03556007Phase 1
- A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)TerminatedNCT04677179Phase 2
- NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin LymphomaCompletedNCT04136756Phase 1
- Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for RecurrenceTerminatedNCT04410445Phase 3
- A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and CapecitabineCompletedNCT02915744Phase 3
- A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)TerminatedNCT03729245Phase 3
- A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial CancerCompletedNCT03785925Phase 2
- A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid TumorsCompletedNCT02983045Phase 1/2
- Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid TumorsTerminatedNCT03138889Phase 1/2
- REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor MalignanciesTerminatedNCT03435640Phase 1/2
- BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)TerminatedNCT04969861Phase 2/3
- A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee PainCompletedNCT01619839Phase 2
- A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid TumorsCompletedNCT02869295Phase 1/2
- An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 StudiesCompletedNCT01457118Phase 2
- NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal CancerCompletedNCT00856375Phase 2
- NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)CompletedNCT00598975Phase 2
- Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian CancerCompletedNCT00806156Phase 2
- A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dependent Recreational Opioid Users.TerminatedNCT03802227Phase 1
- A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and NivolumabWithdrawnNCT04955262Phase 1
- Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Cancer PainCompletedNCT02367820Phase 3
- The BEACON Study (Breast Cancer Outcomes With NKTR-102)CompletedNCT01492101Phase 3
- Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back PainCompletedNCT02362672Phase 3
- Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast CancerCompletedNCT00802945Phase 2
- A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Etirinotecan Pegol)CompletedNCT01991678Phase 1
- A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and SafetyCompletedNCT01976143Phase 1